The PROGRESS Study: Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implants Following Surgical Opening of the Frontal Sinus for Chronic Sinusitis: A Randomized Blinded Controlled Study

Trial Profile

The PROGRESS Study: Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implants Following Surgical Opening of the Frontal Sinus for Chronic Sinusitis: A Randomized Blinded Controlled Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2017

At a glance

  • Drugs Mometasone (Primary)
  • Indications Sinusitis
  • Focus Registrational; Therapeutic Use
  • Acronyms PROGRESS
  • Sponsors Intersect ENT
  • Most Recent Events

    • 24 Feb 2017 According to an Intersect ENT media release, based on the PROPEL Contour cohort of this study company has received approval from the U.S. FDA for its PROPEL Contour steroid releasing sinus implant for Use in treating the frontal and maxillary sinuses.
    • 01 Aug 2016 According to an Intersect ENT media release, based on the NOVA cohort of this study the company has submitted a supplemental premarket approval submission (PMA-s) to the U.S. Food and Drug Administration seeking approval for the NOVA steroid releasing implant for patients with chronic sinus disease.
    • 11 Jul 2016 Results for Propel Mini cohort published in an Intersect ENT media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top